COVID-19 vaccine doses and administration

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

≥12 years

Presentation

Multidose vial without preservative. Each vial contains 6 doses in 0.45 mL. Requires dilution with 1.8 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour

Purple

Volume/strength

0.3 mL (30 µg) per dose

Schedule

2 doses, 3 to 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.3 mL dose contains 30 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

• ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
• 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
• distearoylphosphatidylcholine (DSPC)
• cholesterol
• potassium chloride
• monobasic potassium phosphate
• sodium chloride
• dibasic sodium phosphate dihydrate
• sucrose
• water for injection

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

5 to <12 years

Presentation

Tris/sucrose presentation. Multidose vial containing 10 doses in 1.3 mL. Requires dilution with 1.3 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour

Orange

Volume/strength

0.2 mL (10 µg) per dose

Schedule

2 doses, 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.2 mL dose contains 10 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

• ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
• 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
• distearoylphosphatidylcholine (DSPC)
• cholesterol
• trometamol
• trometamol hydrochloride
• sucrose
• water for injection

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

6 months to <5 years

Presentation

Tris/sucrose presentation. Multidose vial containing 10 doses in 0.4 mL. Requires dilution with 2.2 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour

Maroon

Volume/strength

0.2 mL (3 µg) per dose

Schedule

3 doses, each dose 8 weeks apart

Administration route

For infants aged 6 to 12 months: Intramuscular injection into vastus lateralis muscle of the anterolateral thigh

For children aged ≥12 months: Intramuscular injection into deltoid muscle (or into the vastus lateralis muscle of the anterolateral thigh)

Ingredients

Each 0.2 mL dose contains 3 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

• ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
• 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
• distearoylphosphatidylcholine (DSPC)
• cholesterol
• trometamol
• trometamol hydrochloride
• sucrose
• water for injection

Sponsor

Moderna Australia Pty Ltd

Approved age for use

≥6 years

Presentation

5 mL multidose vial without preservative

Cap colour

Red

Volume/strength

For children aged 6 to 11 years: 0.25 mL per dose

For people aged ≥12 years as a primary course: 0.5 mL per dose

For people aged ≥18 years as a booster: 0.25 mL per dose

Schedule

For children aged 6 to 11 years: 2 doses, 8 weeks apart

For people aged ≥12 years: 2 doses, 4 to 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 100 μg mRNA encoding the SARS-CoV-2 spike glycoprotein (50 ug in each 0.25 mL dose)

Excipients

• heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
• cholesterol
• distearoylphosphatidylcholine
• 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
• trometamol
• trometamol hydrochloride
• acetic acid
• sodium acetate trihydrate
• sucrose
• water for injection

Sponsor

Moderna Australia Pty Ltd

Approved age for use

6 months to 5 years

Presentation

2.5 mL multidose vial without preservative

Cap colour

Blue. Note that the Moderna bivalent vaccine also has a blue cap. To minimise the risk of administration errors, providers should preferably prepare and store doses of these vaccines separately. Doses withdrawn in advance of administration should be clearly labelled.

Volume/strength

0.25 mL per dose

Schedule

2 doses, 8 weeks apart

Administration route

For infants aged <12 months: Intramuscular injection into vastus lateralis muscle of the anterolateral thigh

For children aged ≥12 months: Intramuscular injection into deltoid muscle (or into the vastus lateralis muscle of the anterolateral thigh)

Ingredients

Each 0.25 mL dose contains 25 μg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

• heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
• cholesterol
• distearoylphosphatidylcholine
• 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
• trometamol
• trometamol hydrochloride
• acetic acid
• sodium acetate trihydrate
• sucrose
• water for injection

Sponsor

Moderna Australia Pty Ltd

Approved age for use

≥18 years

Presentation

2.5 mL multidose vial without preservative

Cap colour

Blue. Note that the Moderna 6 months to 5 years formulation also has a blue cap. To minimise the risk of administration errors, providers should preferably prepare and store doses of these vaccines separately. Doses withdrawn in advance of administration should be clearly labelled.

Volume/strength

0.5 mL per dose

Schedule

1 dose, 3 months after last dose

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 25 μg elasomeran (ancestral SARS-CoV-2) and 25 μg imlasomeran (Omicron BA.1 subvariant)

Excipients

• heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
• cholesterol
• distearoylphosphatidylcholine
• 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
• trometamol
• trometamol hydrochloride
• acetic acid
• sodium acetate trihydrate
• sucrose
• water for injection

Sponsor

AstraZeneca Pty Ltd

Approved age for use

≥18 years

Presentation

Multidose vial without preservative, each vial containing either 8 doses in 4 mL or 10 doses in 5 mL

Volume/strength

0.5 mL per dose

Schedule

2 doses, 4 to 12 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 5 x 10¹⁰ viral particles of ChAdOx1-S, a recombinant, non-replicating chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein

Excipients

• histidine
• histidine hydrochloride monohydrate
• sodium chloride
• magnesium chloride hexahydrate
• disodium edetate (EDTA)
• sucrose
• ethanol absolute
• polysorbate 80
• water for injection

Sponsor

Biocelect Pty Ltd on behalf of Novavax Ltd

Approved age for use

≥12 years

Presentation

Multidose vial without preservative, each vial containing 10 doses in 5 mL

Volume/strength

5 µg antigen, 50 µg Matrix-M

Schedule

2 doses, 3 to 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 5 µg of SARS-CoV-2 spike protein, adjuvanted with Matrix-M.

Adjuvant Matrix-M contains Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract

Excipients

• dibasic sodium phosphate heptahydrate
• monobasic sodium phosphate monohydrate
• sodium chloride
• polysorbate 80
• sodium hydroxide (for adjustment of pH)
• hydrochloric acid (for adjustment of pH)
• water for injection
• adjuvant (Matrix M)
  • Quillaja saponaria saponins fraction A
  • Quillaja saponaria saponins fraction C
  • cholesterol
  • phosphatidyl choline
  • monobasic potassium phosphate
  • potassium chloride